Sirolimus Use in Refractory Crohn's Disease-Reference-Cited by-同舟云学术

Sirolimus Use in Refractory Crohn's Disease

Published:2024-06 Issue:6 Volume:11 Page:e01368
ISSN:2326-3253
Container-title:ACG Case Reports Journal
language:en
Short-container-title:ACG Case Rep J

Author:

Siu Rex K.¹^ORCID,Karime Christian¹,Hashash Jana G.²,Kinnucan Jami²,Picco Michael F.²,Farraye Francis A.²

Affiliation:

1. Department of Internal Medicine, Mayo Clinic Florida, Jacksonville, FL

2. Inflammatory Bowel Disease Center, Mayo Clinic Florida, Jacksonville, FL

Abstract

ABSTRACT Treatment options for patients with inflammatory bowel disease are constantly evolving; however, medication-refractory disease remains an issue. Pediatric case series show the potential benefit of sirolimus therapy in refractory Crohn's disease (CD); however, limited data exist in adult patients. As such, we retrospectively identified and report clinical outcomes for 4 patients prescribed sirolimus for treatment of refractory CD. Despite a median sirolimus therapy duration of 524 days and some therapeutic benefits, all patients discontinued therapy due to adverse effects. Our findings suggest that while sirolimus may have clinical utility, its role may be limited by treatment-derived adverse effects.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference10 articles.

1. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease?;Tsui;Ann Gastroenterol,2018

2. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management;Gomollón;J Crohns Colitis.,2017

3. Sirolimus: Its discovery, biological properties, and mechanism of action;Sehgal;Transplant Proc.,2003

4. The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children;Mutalib;J Crohns Colitis.,2014

5. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases;Herrera-deGuise;Front Med (Lausanne).,2023